| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 04/18/2002 | US20020044928 Immunization of dairy cattle with chimeric GapC protein against streptococcus infection |
| 04/18/2002 | US20020044927 Use of granulysin as an antimicrobial agent |
| 04/18/2002 | US20020044910 Mouthwash compositions |
| 04/18/2002 | DE10122447A1 Biphenylcarboxamide Biphenylcarboxamides |
| 04/18/2002 | CA2462681A1 Disease prevention by reactivation of the thymus |
| 04/18/2002 | CA2462073A1 Hematopoietic stem cell gene therapy |
| 04/18/2002 | CA2462027A1 Stimulation of thymus for vaccination development |
| 04/18/2002 | CA2459746A1 Pyrimidinone derivatives and their use in the treatment of atherosclerosis |
| 04/18/2002 | CA2425815A1 Treatment of t cell disorders |
| 04/18/2002 | CA2425678A1 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | CA2425674A1 Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | CA2425632A1 Agents for the treatment of viral infections |
| 04/18/2002 | CA2425610A1 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 04/18/2002 | CA2425581A1 Modulation of ligand binding/enzymatic activity of alpha beta proteins |
| 04/18/2002 | CA2425508A1 Targeted therapeutic agents |
| 04/18/2002 | CA2425416A1 Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and methods for preparing same |
| 04/18/2002 | CA2425407A1 Protecting therapeutic compositions from host-mediated inactivation |
| 04/18/2002 | CA2425121A1 Ether compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | CA2425001A1 Novel serine protease genes related to dppiv |
| 04/18/2002 | CA2424983A1 Nucleic acid molecules and polypeptides for immune modulation |
| 04/18/2002 | CA2424444A1 Topical antibiotic composition for treatment of eye infection |
| 04/18/2002 | CA2424433A1 Bvh-a2 and bvh-a3 antigens of group b streptococcus |
| 04/18/2002 | CA2424292A1 Tricyclic compounds and uses thereof |
| 04/18/2002 | CA2424055A1 Medication delivery devices |
| 04/18/2002 | CA2423515A1 Pyrazole derivatives for the treatment of viral diseases |
| 04/18/2002 | CA2422718A1 Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins |
| 04/18/2002 | CA2394084A1 Inhibitors of protein kinases |
| 04/17/2002 | EP1197218A1 Algae protein polysaccharide extraction and use thereof |
| 04/17/2002 | EP1196635A2 Cell death related drug targets in yeast and fungi |
| 04/17/2002 | EP1196616A2 Replication-competent anti-cancer vectors |
| 04/17/2002 | EP1196608A2 Novel antifungal agents and fungicides, method for the production thereof and their use |
| 04/17/2002 | EP1196607A1 Chlamysin b antibacterial protein, gene encoding it and an expression system for it |
| 04/17/2002 | EP1196595A2 Methods of inducing cell death |
| 04/17/2002 | EP1196587A2 Antigenic meningococcal peptides |
| 04/17/2002 | EP1196586A1 Basb111 polypeptide and polynucleotide from moraxella catharrhalis |
| 04/17/2002 | EP1196584A1 Tetanus toxin polypeptides |
| 04/17/2002 | EP1196577A2 Cell cycle and proliferation proteins |
| 04/17/2002 | EP1196574A2 Human proteins involved in detoxification |
| 04/17/2002 | EP1196569A2 Electron transfer proteins |
| 04/17/2002 | EP1196568A1 Human lim domain proteins |
| 04/17/2002 | EP1196567A2 Human immune response molecules |
| 04/17/2002 | EP1196559A1 Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
| 04/17/2002 | EP1196552A2 Methods and compositions for engineering of attenuated vaccines |
| 04/17/2002 | EP1196443A2 Erythropoietin conjugates with polyethylenglycol |
| 04/17/2002 | EP1196441A1 Keratinocyte growth factor-2 |
| 04/17/2002 | EP1196439A2 Compounds exhibiting an antibiotic activity |
| 04/17/2002 | EP1196437A1 Fima PILUS-BASED VACCINES |
| 04/17/2002 | EP1196433A2 CYCLIC PEPTIDE DERIVATIVES AS INHIBITORS OF INTEGRIN ALPHA v BETA 6 |
| 04/17/2002 | EP1196411A1 Bradykinin b1 receptor antagonists |
| 04/17/2002 | EP1196410A1 Respiratory syncytial virus replication inhibitors |
| 04/17/2002 | EP1196409A2 Respiratory syncytial virus replication inhibitors |
| 04/17/2002 | EP1196408A1 Respiratory syncytial virus replication inhibitors |
| 04/17/2002 | EP1196407A1 N-imidazolylmethyl carboxamides as nitric oxide production inhibitors |
| 04/17/2002 | EP1196406A1 Amino ceramide-like compounds and therapeutic methods of use |
| 04/17/2002 | EP1196404A1 Piperazine derivatives as modulators of chemokine receptor activity |
| 04/17/2002 | EP1196390A2 Pyrazole compositions useful as inhibitors of erk |
| 04/17/2002 | EP1196384A1 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof |
| 04/17/2002 | EP1196197A2 Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene |
| 04/17/2002 | EP1196193A2 Interleukin-1 muteins useful as vaccine adjuvants |
| 04/17/2002 | EP1196191A1 Death domain containing receptor 5 |
| 04/17/2002 | EP1196188A1 Vgf selective binding agents and methods of treating vgf-related disorders |
| 04/17/2002 | EP1196180A1 Treatment of angiogenesis dependent conditions with dextrin sulphate |
| 04/17/2002 | EP1196173A2 Tetrahydroquinolinyl-6-methyldihydrothiadiazinone derivatives and use thereof |
| 04/17/2002 | EP1196169A1 Compounds having cytokine inhibitory activity |
| 04/17/2002 | EP1196159A1 Use of tosylchloramide(s) for treating diseases of the skin, mucous membranes, organs and tissues |
| 04/17/2002 | EP1196155A1 New use of compounds as antibacterial agents |
| 04/17/2002 | EP1196136A1 Compositions comprising organosiloxane resins for delivering oral care substances |
| 04/17/2002 | EP1196135A1 Compositions comprising organosiloxane resins for delivering oral care substances |
| 04/17/2002 | EP1196043A1 An effervescent green tea extract formulation |
| 04/17/2002 | EP1112079B1 Myrtle extract, preparation method and use |
| 04/17/2002 | EP0863767B1 Powdery iodine complexes |
| 04/17/2002 | EP0805156B1 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same |
| 04/17/2002 | CN1345375A Streptococcus pneumoniae antigens |
| 04/17/2002 | CN1345335A Melanocortin receptor ligands |
| 04/17/2002 | CN1345333A Echinocandin/carbohydrate complexes |
| 04/17/2002 | CN1345332A C-terminal modified (N-substituted)-2 indolylcarbonyldiptides as inhibitors of ICE/CED-3 family of cysteine proteases |
| 04/17/2002 | CN1345331A Method and composition for angiogenesis inhibition |
| 04/17/2002 | CN1345329A Tumor mecrosis factor receptors 6 alpha and beta |
| 04/17/2002 | CN1345321A Optically pure camptothecin analogues |
| 04/17/2002 | CN1345312A Dibenzoazulene derivatives for treating thrombosis, osteoporosis arteriosclerosis |
| 04/17/2002 | CN1345308A Acetylenic alpha-amino acid based sulfonamide hydroxamic acid TACE inhibitors |
| 04/17/2002 | CN1345245A Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 04/17/2002 | CN1345243A Drugs, foods, drinks and feeds containing cocoa component |
| 04/17/2002 | CN1345230A Processes for making pharmaceutical oral ECB formulations and compositions |
| 04/17/2002 | CN1345229A Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
| 04/17/2002 | CN1345189A Nutritional compositions with contain slightly negatively charged, non-digestible polysaccharides and use thereof for reducing transport through tight junctions |
| 04/17/2002 | CN1344563A Medicine for treating hepatitis B and other hepatosis |
| 04/17/2002 | CN1344562A Externally used cold-evil expelling prepn |
| 04/17/2002 | CN1082819C United pharmaceutical system for abrogation of viral resistance to nucleoside analogues by double-stranded RNAS |
| 04/17/2002 | CN1082809C 肥皂组合物 Soap compositions |
| 04/16/2002 | US6372956 Transgenic rats and rat cell lines expressing human CD4 and a human chemokine receptor |
| 04/16/2002 | US6372888 Useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications |
| 04/16/2002 | US6372883 For therapy and prophylaxis of infections caused by hepatitis c, hepatitis g and human gb viruses |
| 04/16/2002 | US6372778 Sulfonamide inhibitors of aspartyl protease |
| 04/16/2002 | US6372777 Cyclic AMP-specific phosphodiesterase inhibitors |
| 04/16/2002 | US6372768 2-aminopyridines containing fused ring substituents |
| 04/16/2002 | US6372754 Drugs for treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpic neuralgia. |
| 04/16/2002 | US6372751 Drugs with benzene and pyrimidine rings |
| 04/16/2002 | US6372499 Transfection efficiency |
| 04/16/2002 | US6372487 Polynucleotides encoding peptide release factor, prfC (RF-3), a GTP-binding protein |